Inogen CMO Stanislav Glezer departs; severance includes 12-month salary & COBRA

Inogen Inc

Dr. Stanislav Glezer separated as EVP R&D and Chief Medical Officer effective April 11, 2024.
Severance: 12 months base salary of $505,000 (26 pay periods) and COBRA premium reimbursement for 12 months.
Unvested equity awards forfeited; vested stock options remain exercisable per plan terms.
No annual bonus owed; tuition repayment for CEO program waived.
Separation agreement includes standard release of claims and confidentiality obligations.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stanislav Glezer

Executive Vice President, R&D and Chief Medical Officer

INGN · Inogen Inc

Effective: 2024-04-11
Filed: May 15, 2024, 7:59 PM ET

Dr. Glezer’s role as an officer and employee of the Company ended effective April 11, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stanislav Glezer departed as Executive Vice President, R&D and Chief Medical Officer at Inogen Inc.

Action: separated
Role: Executive Vice President, R&D and Chief Medical Officer

Exact text from the filing

Dr. Glezer’s role as an officer and employee of the Company ended effective April 11, 2024

View on SEC.gov

Inogen Inc filing history →

Source: SEC EDGAR

accession 0000950170-24-060589

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.